Annovis Bio CEO Selected as a Finalist in the 2021 PACT Enterprise Awards
Berwyn, Pennsylvania--(Newsfile Corp. - June 24, 2021) - Annovis Bio, Inc. (NYSE American: ANVS), ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced its CEO, Maria L. Maccecchini, Ph.D., was selected as a Life Sciences and Healthcare CEO finalist in the 2021 PACT Enterprise Awards.
Hosted by the Philadelphia Alliance for Capital and Technologies (PACT), whose vision is to be the go-to resource for fast growing companies and a driver of entrepreneurship and innovation in the Philadelphia region, the PACT Enterprise Awards is a two-night, hybrid event featuring an in-person celebration on June 29 and an online broadcast of the Enterprise Awards ceremony on June 30, presented by Fairmount Partners and KPMG.
The awards ceremony will take place from 4:30 p.m. to 5:30 p.m. ET on June 30 and can be viewed online: https://www.youtube.com/watch?v=KSzTe3dY0RY.
As part of the 28th annual awards event, PACT hosted a panel, "Legends and Leaders," in which Dr. Maccecchini was a speaker. She participated in the discussion with past PACT Enterprise Awards Legend Honorees and other business leaders. The June 23 panel discussed the unique challenges and lessons learned from the past year as well as the current business environment and opportunities for the future.
Watch the PACT Legends and Leaders panel discussion: https://youtu.be/0KMvEdWLhiE
Watch the PACT Enterprise Awards finalist announcement: https://youtu.be/kL9qslKRDG0
About Annovis Bio Inc.
Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD) and Alzheimer's in Down Syndrome (AD-DS). We believe that we are the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. We expect our treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. We have two ongoing Phase 2a studies: one in AD patients and one in both AD and PD patients. For more information on Annovis, please visit the company's website: www.annovisbio.com.
Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "expect," "believe," "will," "may," "should," "estimate," "project," "outlook," "forecast" or other similar words, and include, without limitation, statements regarding the timing, effectiveness, and anticipated results of ANVS401 clinical trials. Forward-looking statements are based on Annovis Bio, Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in the Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Annovis Bio, Inc. undertakes no duty to update such information except as required under applicable law.
Dave Gentry, CEO
RedChip Companies Inc.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/88530